key: cord-0901167-zhjoyuyj
authors: Sachs, Jeffrey R.; Gibbs, Kevin W.; Swor, Dionne E.; Sweeney, Adam P.; Williams, Daniel W.; Burdette, Jonathan H.; West, Thomas G.; Geer, Carol P.
title: COVID-19–associated Leukoencephalopathy
date: 2020-05-14
journal: Radiology
DOI: 10.1148/radiol.2020201753
sha: 9e6c056858ee142bb3f29bf2d4a9c17f7a26b314
doc_id: 901167
cord_uid: zhjoyuyj

nan

Conflicts of interest are listed at the end of this article. Radiology 2020; 296:E184-E185 • https://doi.org/10.1148/radiol.2020201753 • © RSNA, 2020 count of 175 000/mL, an activated partial thromboplastin clotting time of 34.7 seconds, an international normalized ratio of 1.3, a D-dimer level of 11 720 ng/mL, and a fibrinogen level of 693 mg/dL. Lumbar puncture was not performed.

Unenhanced head CT images showed subtle hypoattenuation of the bilateral cerebral hemispheric white matter and corpus callosum (Fig 1) . T2-weighted fluid-attenuated inversion recovery MRI scans of the brain revealed diffuse, confluent posterior predominant white matter hyperintensities, scattered microhemorrhages predominantly in the corpus callosum, and apparent posterior circulation hyperperfusion (Fig 2) , without diffusion restriction or abnormal enhancement.

These imaging findings are nonspecific and can accompany several well-established leukoencephalopathies. Confluent corpus callosal involvement can occur in acute disseminated encephalomyelitis (1) or acute hemorrhagic encephalomyelitis (2) . Microbleeds can be seen with these or other vasculitides (3), as well as with posterior reversible encephalopathy syndrome (note that there was no documented hypertension in this case). Anesthesia-related toxicity is also possible. Although the mechanism of white matter injury and its relationship to COVID-19 is uncertain, possibilities include endotheliitis with thrombotic microangiopathy (4) as well as COVID-19-associated cytokine release syndrome, which may have implications for treatment (5) . A s the coronavirus disease 2019 (COVID-19) pandemic has progressed, the recognition of neurologic sequelae has increased. Herein, we report on a case of COVID-19-associated leukoencephalopathy with microhemorrhage.

A 59-year-old man with known persistent asthma (managed with inhaled steroids and long-acting beta agonists) presented with upper respiratory symptoms (10 days duration) and fever (7 days duration). COVID-19 was confirmed by means of polymerase chain reaction assay. He was intubated on hospital day 6. Severe agitation required high-dose analgesics (including dilaudid, fentanyl, and morphine), and blood pressure required intermittent pressor support (mean, 70-90 mm Hg, without sustained hypertension). Laboratory results included a platelet This copy is for personal use only. To order printed copies, contact reprints@rsna.org 

Acute disseminated encephalomyelitis: complication of a vaccine preventable disease

Acute hemorrhagic leukoencephalitis with severe brainstem and spinal cord involvement: MRI features with neuropathological confirmation

Imaging spectrum of CNS vasculitis

Endothelial cell infection and endotheliitis in COVID-19

Cytokine release syndrome in severe COVID-19